GlycoEra AG

Swiss Biotech Association

Member

GlycoEra leverages its control over natural glycan-mediated pathways to advance novel drugs using its propriety platform, the CustumGlycan Platform. GlycoEra develops first in class therapeutics in inflammatory disease, autoimmune disorder and immuno-oncology indications.

https://glycoera.com/
+41 44 733 85 75
veronica.gambillara@glycoera.com
Veronica Gambillara Fonck

Location

Grabenstrasse 3, 8952 Schlieren, Zürich, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2020
Number of employees in Switzerland

10-19

Key business

Core competencies

You may also be interested in

BioXpress Therapeutics SA

BioXpress Therapeutics SA is exclusively focused on the development of biosimilars. With a philosophy that everyone should have access to high quality biologic therapeutics, BioXpress brings speed, efficiency and safety in developing biosimilar mAbs that impact patients’ quality of life.
1202 Geneva

Not a member

Adoram Therapeutics SA

Adoram Therapeutics is developing a suite of small molecule allosteric modulators for different indications. Our primary asset in the preclinical stage, is a negative allosteric modulator (NAM) of a clinically validated immuno-oncology target - the adenosine 2A receptor (A2AR).
1212 Grand-Lancy

Member

Hengrui Europe Biosciences AG

Hengrui Europe Biosciences is a biotech start-up based in Zurich, Switzerland, established in 2021. We are a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. and are building a new research center with a differentiated technology platform to support innovative antibody discovery research.
8048 Zürich

Member